Anti-p200 Pemphigoid Mimicking Acquired Reactive Perforating Collagenosis
DOI:
https://doi.org/10.2340/actadv.v104.40627Keywords:
Anti-p200 Pemphigoid, Autoimmune blistering disease, Acquired reactive perforating collagenosisAbstract
Abstract is missing (Short communication)
Downloads
References
Chen KR, Shimizu S, Miyakawa S, Ishiko A, Shimizu H, Hashimoto T. Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous dermatosis: identification of a novel 200-kDa lower lamina lucida target antigen. Br J Dermatol 1996; 134: 340-346.
https://doi.org/10.1111/j.1365-2133.1996.tb07625.x
van Beek N, Weidinger A, Schneider SW, Kleinheinz A, Glaser R, Holtsche MM, et al. Incidence of pemphigoid diseases in Northern Germany in 2016: first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J Eur Acad Dermatol Venereol 2021; 35: 1197-1202.
https://doi.org/10.1111/jdv.17107
Zillikens D, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106: 465-470.
https://doi.org/10.1111/1523-1747.ep12343631
Kridin K, Ahmed AR. Anti-p200 pemphigoid: a systematic review. Front Immunol 2019; 10: 2466.
https://doi.org/10.3389/fimmu.2019.02466
Goletz S, Pigors M, Lari TR, Hammers CM, Wang Y, Emtenani S, et al. Laminin beta4 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid. J Am Acad Dermatol 2024; 90: 790-797.
https://doi.org/10.1016/j.jaad.2023.11.014
Goletz S, Probst C, Komorowski L, Radzimski C, Mindorf S, Holtsche MM, et al. Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin beta4 subunit. Br J Dermatol 2024; 191: 140-141.
https://doi.org/10.1093/bjd/ljae136
Goletz S, Hashimoto T, Zillikens D, Schmidt E. Anti-p200 pemphigoid. J Am Acad Dermatol 2014; 71: 185-191.
https://doi.org/10.1016/j.jaad.2014.02.036
Semeria L, Lamiaux M, Quinchon JF, Modiano P. Anti-p200 pemphigoid mimicking erythema multiforme. JAAD Case Rep 2022; 21: 157-159.
https://doi.org/10.1016/j.jdcr.2022.01.011
Wagner G, Sachse MM. Acquired reactive perforating dermatosis. J Dtsch Dermatol Ges 2013; 11: 723-729, 723-730.
https://doi.org/10.1111/ddg.12131
Kakehi Y, Miyagawa F, Ogawa K, Hashimoto T, Asada H. Case of anti-laminin gamma1 pemphigoid associated with ulcerative colitis and acquired perforating dermatosis. J Dermatol 2021; 48: e35-e36.
https://doi.org/10.1111/1346-8138.15624
Maki N, Nishie W, Takazawa M, Kakurai M, Yamada T, Umemoto N, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis. J Dermatol 2018; 45: 600-602.
https://doi.org/10.1111/1346-8138.14254
Nomura H, Mukai M, Niimi Y, Egami S, Yokoyama T, Sugiura M, et al. Coexistence of acquired perforating dermatosis and bullous pemphigoid: three cases. Eur J Dermatol 2017; 27: 192-193.
https://doi.org/10.1684/ejd.2016.2944
Schauer F, Kern JS, Virtic O, Technau-Hafsi K, Meiss F, Thoma K, et al. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid. Br J Dermatol 2019; 180: 231-232.
https://doi.org/10.1111/bjd.17146
Tani S, Ishii N, Hashimoto T, Tsujioka K. Bullous pemphigoid arising in a patient with acquired perforating dermatosis. Clin Exp Dermatol 2017; 42: 406-409.
https://doi.org/10.1111/ced.13080
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Janik Fleißner, Katrin Ickrath, Matthias Goebeler, Sandrine Benoit, Andreas Kerstan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.